Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Burke
George W
GW
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, PO Box 012440, Miami, FL 33101, USA. GBurke@med.miami.edu
Ciancio
C
C
Blomberg
B B
BB
Rosen
A
A
Suzart
K
K
Roth
D
D
Kupin
W
W
Esquenazi
V
V
Miller
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D020123:Sirolimus / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016559:Tacrolimus / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors / Q000706:statistics & numerical data
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000077561:Daclizumab; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus